PTCT (PTC Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

PTCT (PTC Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

PTCTPTC Therapeutics, Inc.

Mkt Cap$6B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$1.7B

Net Income (TTM)$683M

EPS (TTM)$7.74

Free Cash Flow (TTM)$699M

Gross Margin91.0%

Op. Margin49.5%

Net Margin39.4%

FCF Margin40.4%

P/S Ratio (TTM)3.4x

P/E Ratio (TTM)8.6x

YoY Rev Growth+114.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$220M	$206M	-$118M
Q2 23	$214M	$201M	-$210M
Q3 23	$197M	$187M	-$118M
Q4 23	$307M	$201M	$3M
Q1 24	$210M	$195M	-$45M
Q2 24	$187M	$171M	-$40M
Q3 24	$197M	$186M	-$55M
Q4 24	$213M	$197M	-$162M
Q1 25	$1.2B	$1.2B	$970M
Q2 25	$179M	$167M	-$35M
Q3 25	$211M	$95M	$3M
Q4 25	$165M	$148M	-$82M

Valuation

Quarter	P/S	P/E
Q1 23	7.6x	—
Q2 23	7.1x	—
Q3 23	7.3x	—
Q4 23	6.2x	—
Q1 24	6.3x	—
Q2 24	6.5x	—
Q3 24	6.5x	—
Q4 24	7.2x	—
Q1 25	3.3x	9.8x
Q2 25	3.3x	9.3x
Q3 25	3.3x	7.8x
Q4 25	3.4x	8.6x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$29M	-$73M
Q2 23	-$14M	-$33M
Q3 23	-$15M	-$44M
Q4 23	-$100M	-$129M
Q1 24	$71M	$6M
Q2 24	-$71M	-$64M
Q3 24	-$77M	-$88M
Q4 24	-$30M	-$37M
Q1 25	$870M	$868M
Q2 25	-$58M	-$62M
Q3 25	-$66M	-$70M
Q4 25	-$34M	-$37M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$44M
Q2 23	$19M
Q3 23	$29M
Q4 23	$28M
Q1 24	$64M
Q2 24	$7M
Q3 24	$11M
Q4 24	$6M
Q1 25	$3M
Q2 25	$4M
Q3 25	$3M
Q4 25	$2M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+48.2%	+43.7%
Q2 23	+29.2%	+64.2%
Q3 23	-9.5%	+8.3%
Q4 23	+83.4%	-17.4%
Q1 24	-4.7%	-24.4%
Q2 24	-12.7%	-46.4%
Q3 24	+0.1%	-20.2%
Q4 24	-30.6%	+23.6%
Q1 25	+459.7%	-19.4%
Q2 25	-4.2%	-5.8%
Q3 25	+7.2%	-17.2%
Q4 25	-22.7%	-34.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$29M	13.1%
Q2 23	$59M	27.6%
Q3 23	$27M	13.7%
Q4 23	$17M	5.4%
Q1 24	$18M	8.7%
Q2 24	$19M	10.3%
Q3 24	$20M	10.0%
Q4 24	$17M	8.1%
Q1 25	$18M	1.5%
Q2 25	$19M	10.4%
Q3 25	$19M	9.2%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$195M	—	$87M
Q2 23	$186M	—	$88M
Q3 23	$164M	$81M	—
Q4 23	$121M	$81M	—
Q1 24	$116M	—	$73M
Q2 24	$132M	—	$70M
Q3 24	$161M	—	$73M
Q4 24	$125M	—	$85M
Q1 25	$109M	—	$81M
Q2 25	$113M	—	$85M
Q3 25	$100M	—	$84M
Q4 25	$133M	—	$100M

Revenue Segments

Quarter	Manufacturing	Product	Royalty	Collaboration and License Revenue
Q2 24	$800K	$133M	$53M	—
Q3 24	$800K	$135M	$61M	—
Q1 25	—	$153M	$36M	$986M
Q2 25	—	$118M	$58M	$3M
Q3 25	—	$131M	$71M	$9M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$167M	$119M	$286M
Q2 23	$208M	$130M	$338M
Q3 23	$165M	$130M	$295M
Q4 23	$594M	$283M	$877M
Q1 24	$548M	$336M	$885M
Q2 24	$655M	$439M	$1.1B
Q3 24	$526M	$487M	$1.0B
Q4 24	$780M	$360M	$1.1B
Q1 25	$1.5B	$547M	$2.0B
Q2 25	$1.0B	$972M	$2.0B
Q3 25	$673M	$1.0B	$1.7B
Q4 25	$985M	$961M	$1.9B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	74M	+1.5%
Q2 23	75M	+1.4%
Q3 23	75M	+0.9%
Q4 23	76M	+0.2%
Q1 24	76M	+1.3%
Q2 24	77M	+0.3%
Q3 24	77M	+0.3%
Q4 24	77M	+0.4%
Q1 25	86M	+11.9%
Q2 25	78M	-9.5%
Q3 25	87M	+11.5%
Q4 25	81M	-7.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$119K	193
FY 15	$115K	320
FY 16	$272K	304
FY 17	$521K	373
FY 18	$512K	517
FY 19	$403K	761
FY 20	$394K	967
FY 21	$458K	1K
FY 22	$496K	1K
FY 23	$943K	995
FY 24	$807K	1K
FY 25	$30K	58K